

References

Adams G.P, Schier R and McCall A.M(2001):, High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules. *Cancer Res.* 61:4750-4755

Aires da Silva E, Santa-Marta M. and Freitas –Viera A (2004):, Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity. *J. Mol. Biol.* 340-525-542

Alvarez-Rueda N, Behar G, Ferre V, Pugniere M, Roquet F, Gastinel L, Jacquot C, Aubry J, Baty D, Barbet J and Birkle S (2007) :, Generation of llama single-domain antibodies against methotrexate, a prototypical hapten. *Mol Immunol* 44:1680–1690

Arbabi-Ghahroudi M, Desmyter A, Wyns L, Hamers R and Muyldermans S (1997):, Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. *FEBS Lett* 414:521–526

Arbabi-Ghahroudi M, Tanha J and MacKenzie R (2005):, Prokaryotic expression of antibodies. *Cancer Metastasis Rev* 24:501–519

Auf der maur A, Eschier D and Barberis A(2001):, Antigen-independent selection of stable intracellular single-chain antibodies. *FEBS Lett.* (2001) 508:407-412

Baral T.N, Magez S, Stijlemans B, Conrath K, Vanhollebeke B, Pays E, Muyldermans S and De Baetselier P (2006) :, Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. *Nat Med* 12:580–584

Barclay A and Zinden X (2003):, "Membrane proteins with immunoglobulin-like domains--a master superfamily of interaction molecules". *Semin Immunol* 15 (4): 215–23

Bender E, Woof J.M., Atkin J.D., Barker M.D. , Bebbington C.R. and Burton D.R(1993):, Recombinant human antibodies: linkage of a Fab

Fragment from a combinatorial library to an Fc fragment for expression in mammalian cell culture. *Hum. Antibodies Hybridomas* 4:74-79.

Berard J.L and Freits C (1999):, A review of interleukin-2 receptor antagonists in solid organ transplantations. *Pharmaco-therapy* 19:1127-1137.

Bergman Y and Cedar H (2004):, "A stepwise epigenetic process controls immunoglobulin allelic exclusion". *Nat Rev Immunol* 4 (10): 753–61.

Better M, Chang C.P., Robinson R.R. and Horwitz A.H(1988):, Escherichia coli secretion of an active chimeric antibody. *Science*(240-1041-1043).

Bond C.J., Marsters J.C. and Sidhu SS (2003):, Contributions of CDR3 to VHH domain stability and the design of monobody scaffolds for naive antibody libraries. *J Mol Biol* 332:643–655

Borghesi L and Milcarek C (2006):, "From B cell to plasma cell: regulation of V(D)J recombination and antibody secretion". *Immunol Res* 36 (1-3): 27–32

Borrebaeck Cak , Malmberg A.C and Furebring C(1992):, Kinetic analysis of recombinant antibody-antigen interactions relation between structural domains and antigen binding. *Biotechnology* 10: 697-689

Brehm-Stecher B and Johnson E (2004):, "Single-cell microbiology: tools, technologies, and applications". *Microbiol Mol Biol Rev* 68 (3): 538–59.

Burton D., Deilon F(2002):, Antibodies, viruses and vaccines. *Nat. Rev. Immunol.* 2:706-713

Carter P. and Simone A(2001):, Improving the efficacy of antibody-based cancer therapies. *Nat. Rev. Cancer* 1:118-129.

Carter P, Presta L and Gorman C.M.(1992):, Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy. *Proc Natl Acad Sci USA*; 89: 4285-4289.

Casali P and Zan H (2004):, "Class switching and Myc translocation: how does DNA break?". *Nat. Immunol.* 5 (11): 1101–3.

Chaudhury C, Miehnaz S and Robinson J.M.(2003):, The major histocompatibility complex –related Fc receptor for IgG (RcRn) binds albumin and prolongs its lifespan. *J. Exp. Med.* 197: 315-322.

Choy E.H, Hazleman B and Smith M,(2002):, Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a Phase II double-blinded, randomized, dose-escalating trial. *Rheumatology* 41:1133-1137.

Chapman A.P. and Zelan M*2002):, PEGylated antibodies and antibody fragments for improved therapy: a review. *Adv. Drug Deliv. Rev.* 54: 531-545.

Chothia C, Lesk A.M. and Tramontano A(1989):, Confirmations of immunoglobulin hyper variable regions. *Nature* ; 342: 877-883.

Cole SP, Campling BG, Atlaw T, Kozbor D, Roder JC (1984):, "Human monoclonal antibodies". *Mol. Cell. Biochem.* 62 (2): 109–20

Conrath K.E., Vincke C, Stijlemans B, Schymkowitz J, Decanniere K, Wyns L, Muyldermans S and Loris R (2005):, Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. *J Mol Biol* 350:112–125

Conrath K.E., Wernery U, Muyldermans S and Nguyen V.K(2003):, Emergence and evaluation of functional heavy-chain antibodies in Camelidae. *Dev. Comp. Immunol.* 27:87-103

Conrath K.E, Lauwereys M, Galleni M, Matagne A, Frere JM, Kinne J, Wyns L and Muyldermans S (2001a) :, Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. *Antimicrob Agents Chemother* 45:2807–2812

Conrath K.E, Lauwereys M, Wyns L and Muyldermans S (2001b) :, Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. *J Biol Chem* 276:7346–7350

Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, Hostens J, Revets H, Remaut E, Elewaut D and Rottiers P (2006):, Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. *Arthritis Rheum* 54:1856–1866

Cortez-Retomozo V., Backmann N. and Senter P(2004):, Efficient cancer therapy with a nanobody-based conjugate. *Cancer Res.* 64: 2853-2857.

Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, Gobert M, Conrath K, Muyldermans S, De Baetselier P and Revets H (2002):, Efficient tumor targeting by single-domain antibody fragments of camels. *Int J Cancer* 98:456–462

Davies J, and Riechmann L (1996):, Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. *Protein Eng* 9:531–537

Davies J and Riechmann L (1995):, Antibody VH domains as small recognition units. *Biotechnology (NY)* 13:475–479

Davies J. and Reichmann L(1994):, ‘Camelising’ human antibody fragments: NMR studies on VH domains. *FEBS Lett.* 339:285-290

Dean and Laura (2005):, "Chapter 4: Hemolytic disease of the newborn", *Blood Groups and Red Cell Antigens*. NCBI Bethesda (MD): National Library of Medicine (USA).

Decanniere K., Desmyter A., Lauwereys M., Gharoudi M.A., Mulydermans S and Wyns L(1999):, A singledomain antibody fragment in complex with Rnase A: non-canonical loop structures and nanomolar affinity using two CDR loops. *Struct. Fold. Des.* 7: 361-370

Decanniere K., Mulydermans S. and Wyns L(2000):, Canonical antigen-binding loop structures in immunoglobulins: more canonical classes? *J. Mol. Biol.* 300:83-91.

De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, Muyldermans S and Wyns L (2006):, Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. *Proc Natl Acad Sci USA* 103:4586–4591

Dekker S., Toussaint W. and Panayotou G(2003):, Intracellularly expressed single domain antibody against p 15 matrix protein prevents the production of porcine retroviruses. *J. Virol.* 77: 12132-12139

Dennis M.S., Zhang M. and Meng Y.G(2002):, Albumin binding as a general strategy for improving the pharmacokinetics of proteins. *J. Biol. Chem.* 277:35035-35042.

Desmyter A, Decanniere K, Muyldermans S and Wyns L (2001):, Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. *J Biol Chem* 276:26285– 26290

Desmyter A., Spinelli S.,Payane F.,Lauqereys M.,Wyns L. and Mulydermans S(2002):, Three camelid VHH domains in complex with porcine pancreatic alpha amylase. Inhibition and versatility of binding topology. *J. Biol. Chem.* (2002) 277: 23645-23650.

Desmyter A, Transue TR, Ghahroudi MA, Thi MH, Poortmans F, Hamers R, Muyldermans S, Wyns L (1996):, Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. *Nat Struct Biol* 3:803–811

Diaz M and Casali P (2002):, "Somatic immunoglobulin hypermutation". *Curr Opin Immunol* 14 (2): 235–40.

Doggrell S and Davide S. (2003):, "Is natalizumab a breakthrough in the treatment of multiple sclerosis?". *Expert Opin Pharmacother* 4 (6): 999–1001

Dolk E, van der Vaart M, Lutje Hulsik D, Vriend G, de Haard H, Spinelli S, Cambillau C, Frenken L and Verrips T (2005):, Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. *Appl Environ Microbiol* 71:442–450

Dufner P, Jermutus L and Minter R.R. (2006):, Harnessing phage and ribosome display for antibody optimisation. *Trends Biotechnol* 24:523–529

Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, Muyldermans S, Wyns L and Matagne A (2002) :,Single-domain antibody fragments with high conformational stability. *Protein Sci* 11:500–515

Dumoulin M, Last A.M, Desmyter A, Decanniere K, Canet D, Larsson G, Spencer A, Archer DB, Sasse J, Muyldermans S, Wyns L, Redfield C, Matagne A, Robinson CV and Dobson CM (2003):, A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. *Nature* 424:783–788

Durandy A and Merck D. (2003):, "Activation-induced cytidine deaminase: a dual role in class-switch recombination and somatic hypermutation". *Eur. J. Immunol.* 33 (8): 2069–73.

Emil von Behring(2007):, - Biography

Edelman GM and Gally JA (1962):, "The nature of Bence-Jones proteins. Chemical similarities to polypeptide chains of myeloma globulins and normal gamma-globulins". *J. Exp. Med.* 116: 207–27.

Eleonora Market, F and Nina Papavasiliou (2003):, V(D)J Recombination and the Evolution of the Adaptive Immune System *PLoS Biology*1(1): e16.

El Khattabi M, Adams H, Heezius E, Hermans P, Detmers F, Maassen B, van der Ley P, Tommassen J, Verrips T and Stam J (2006):, Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: prospects for therapeutic applications. *Clin Vaccine Immunol* 13:1079–1086

Estell D and Rette V (2006):, Adapting industry practices for the rapid, large-scale manufacture of pharmaceutical proteins. *Bridge* 36:39–44

Ewert S, Huber T, Honegger A. and Pluckthun A (2003):, Biophysical properties of human antibody variable domains. *J. Mol. Biol.* 325:531-553.

Ewert S, Huber T, Honegger A. and Pluckthun A(2003):, Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalisable approach. *Biochemistry* 42: 1517-1528

Ewert S, Cambillau C, Conrath K and Pluckthun A (2002):, Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. *Biochemistry* 41:3628–3636

Faraha R.A., Clinchy B., Herrerral and Vittetaes(1998):, The development of monoclonal antibodies for the therapy of cancer. *Crit. Rev. Eukaryot. Gene Expr.* 8:321-356.

Fanning L.J, Connor A.M and Wu G.E (1996):, "Development of the immunoglobulin repertoire". *Clin. Immunol. Immunopathol.* 79 (1): 1–14

Feldmann M and Maini R (2001):, "Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?". *Annu Rev Immunol* 19: 163–96.

Francis R.J, Sharma S.K and Springer C (2002):, A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. *Br J Cancer* ; 87: 600-607.

Frenken L.G.J, van der Linden R.H, Hermans P.W, Bos J.W, Ruuls R.C, de Geus B and Verrips C.T (2000):, Isolation of antigen specific llama VHH antibody fragments and their high level secretion by *Saccharomyces cerevisiae*. *J Biotechnol* 78:11–21

Frenken L.G.J, Hessing J.G., van den Hondel C.A., Verrips C.T (1998):, Recent Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganisms. *Res. Immunol.* 149:589-598.

Fung Kee Fung K, Eason E, Crane J, Armson A, De La Ronde S, Farine D, Keenan-Lindsay L, Leduc L, Reid G, Aerde J, Wilson R, Davies G, Désilets V, Summers A, Wyatt P and Young D (2003):, "Prevention of Rh alloimmunization". *J Obstet Gynaecol Can* **25** (9): 765–73

Gerngross TU and Morris S (2004):, Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. *Nat Biotechnol* 22:1409–1414

Ghaffer A and Lauren S (2006):, "Immunization". *Immunology - Chapter 14*. University of South Carolina School of Medicine.

Gharhoudi M.A., Desmyter A., Wyns L., Hamers R. and Mulydermans S (1997):, Selection and identification of single-domain antibody fragments from camel heavy-chain antibodies. *FEBS Lett.* 414: 521-526.

Geisberger R, Lamers M and Achatz G (2006). "The riddle of the dual expression of IgM and IgD". *Immunology* **118** (4): 429–37.

Glockshuber R, Malia M, Pfitzinger I and Pluckthun A (1990) :, A comparison of strategies to stabilize immunoglobulin Fv-fragments. *Biochemistry* 29:1362–1367

Goding J and Rabat C (1980) . "Allotypes of IgM and IgD receptors in the mouse: a probe for lymphocyte differentiation". *Contemp Top Immunobiol* **8**: 203–43.

Goldman E.R, Anderson G.P, Liu J.L, Delehanty J.B, Sherwood L.J, Osborn L.E, Cummins L.B and Hayhurst A (2006):, Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. *Anal Chem* 78: 8245–8255

Green L.L.,Roth D(1999):, Antibody engineering via genetic engineering of the mouse: Xenomouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. *J. Immunol. Methods* 231:11-23

Greenberg A.S, Avila D, Hughes M, Hughes A, McKinney E.C and Flajnik M.F (1995):, A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. *Nature* 374:168–173

Groothuis J.R. and Nishidah(2002):, Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). *Pediatr. Int.* 44:235-241

Gueorguieva D, Li S, Walsh N, Mukerji A, Tanha J and Pandey S (2006):, Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis. *FASEB J* 20:2636–2638

Gura T and Heinse L(2002):, Therapeutic antibodies: magic bullets hit the target. *Nature* (2002) 417-584-586

Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E.B, Bendahman N and Hamers R (1993):, Naturally occurring antibodies devoid of light chains. *Nature* 363:446–448

Hamilton S.R, Davidson R.C, Sethuraman N, Nett J.H, Jiang Y, Rios S, Bobrowicz P, Stadheim T.A, Li H, Choi B.K, Hopkins D, Wischnewski H, Roser J, Mitchell T, Strawbridge R.R, Hoopes J, Wildt S and Gerngross TU (2006):, Humanization of yeast to produce complex terminally sialylated glycoproteins. *Science* 313:1441–1443

Harmsen M.M, Van Solt C.B, Fijten H.P.D, Van Keulen L, Rosalia R.A, Weerdmeester K, Cornelissen A.H.M, De Bruin M.G.M, Eblé PL and Dekker A (2007):, Passive immunization of guinea-pigs with llama single-domain antibody fragments against foot-and-mouth disease. *Vet Microbiol* 120:193–206

Harmsen M.M, van Solt C.B, van Zijderveld-van Bommel A.M, Ewold TA and van Zijderveld FG (2006):, Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. *Appl Microbiol Biotechnol* 72:544–551

Harmsen MM, Van Solt CB, Fijten HPD and Van Setten MC (2005a) :,Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. *Vaccine* 23:4926–4934

Harmsen MM, van Solt CB, Hoogendoorn A, van Zijderveld FG, Niewold TA and van der Meulen J (2005b):, Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea. *Vet Microbiol* 111:89–98

Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LGJ and de Geus B (2000):, Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. *Mol Immunol* 37:579–590

Harrison R.A, Hasson S.S, Harmsen M, Laing GD, Conrath K and Theakston RD (2006):, Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera. *Toxicon* 47:364–368

Hawkins R.E, RUSSELL S.J and Winter G(1992):, Selction of phage antibodies by binding affinity. Mimickign affinity maturation. *J. Mol. Biol.* 226:889-896.

Heitner T, Moor A, Garrison JL, Marks C, Hasan T and Marks JD (2001):, Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. *J Immunol Methods* 248:17

Henry M.L and Rajab A(2002):,: The use of basiliximab in solid organ transplantation *Expert Opin. Pharmacother*, 3: 1657-1663.

Hermeling S, Crommelin DJ, Schellekens H and Jiskoot W (2004):, Structure–immunogenicity relationships of therapeutic proteins. *Pharm Res* 21:897–903

Heyman B and Damon B (1996):, "Complement and Fc-receptors in regulation of the antibody response". *Immunol Lett* 54 (2-3): 195–9

Holliger P and Hudson PJ (2005):, Engineered antibody fragments and the rise of single domains. *Nat Biotechnol* 23:1126–1136

Holliger P, Wing M, Pound J.D, Bohlen H, and Winter G (1997):, Retargeting serum immunoglobulin with bispecific diabodies. *Nat Biotechnol* 15:632–636

Honjo T and Habu S (1985):, "Origin of immune diversity: genetic variation and selection". *Annu Rev Biochem* 54: 803–30

Hoogenboom H.R., De Bruine A, Hufton S.E., Hoet R.M., Arends J.W and , Roovers R.C (1998):, Antibody phage display technology and its applications. *Immunotechnology* 4:309-318

Hooks M.A, Wade C.S, Millikan W.J. Muromonab C. (1991):, a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. *Pharmacotherapy* 11: 26-37

Hozumi N and Tonegawa S (1976):, "Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions". *Proc. Natl. Acad. Sci. U.S.A.* **73** (10): 3628–32.

Huber R and conve R. (1980):, "Spatial structure of immunoglobulin molecules". *Klin Wochenschr* **58** (22): 1217–31.

Hudson P.J. and Souriau C(2003):, Engineered antibodies. *Nat. Med.* 9:139-134

Hudson P.J.,Souriau C(2001):, Recombinant antibodies for cancer diagnosis and therapy. *Expert Opin. Biol. Ther.* 1:8450855.

Hufton S.E, Van Neer N, Van Den Beuken T, Desmet J., Sablon E. Hoogenboom H.R(2000):, Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands. *FEBS Lett.* 475: 225-231

Huls G.A., Heijen I.A. and Cuomo M.E(1999):, A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. *Nat. Biotechnol.* 17:276-280

Huls G.A., Heijen I.A. and Cuomo M.E(1999): : Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies. *Cancer Res.* 59{5778-5784.

Janeway C.A. ,Charles, Paul Travers, Mark Walport, and Mark Shlomchik (2005):, *Immunobiology.*, 6th ed., Garland Science. ISBN 0-443-07310-4

Janeway C.A., Charles, Paul Travers, Mark Walport, and Mark Shlomchik (2001):, *Immunobiology; Fifth Edition.* New York and London: Garland Science. ISBN 0-8153-4101-6.

Janeway C.A., Charles, Paul Travers, Mark Walport, and Mark Shlomchik I (2001):,. *Immunobiology.*, 5th ed., Garland Publishing. ISBN 0-8153-3642-X.

Janssens R, Dekker S, Hendriks R.W, Panayotou G, van Remoortere A, San J.K, Grosveld F and Drabek D (2006):, Generation of heavychain- only antibodies in mice. *Proc Natl Acad Sci USA* 03:15130–15135

Jespers L, Schon O, Famm K and Winter G (2004):, Aggregation-resistant domain antibodies selected on phage by heat denaturation. *Nat Biotechnol* 22:1161–1165

Jobling A.S., Jarman Clmberg N,Blake C and Verhoeyen M.E(2003):, Immunomodulation of enzyme function in plants by singledomain antibodies. *Nat. Biotechnol.* 21:77-80.

Johansson S.G and Datt A (2006):, "The discovery of immunoglobulin E". *Allergy and asthma proceedings : the official journal of regional and state allergy societies* 27 (2 Suppl 1): S3–6

Joosten V, Roelofs M.S, van den Dries N, Goosen T, Verrips CT, van den Hondel C.A and Lokman B.C (2005):, Production of bifunctional proteins by *Aspergillus awamori*: llama variable heavy chain antibody fragment (V(HH)) R9 coupled to *Arthromyces ramosus* peroxidase (ARP). *J Biotechnol* 120:347–359

Joosten V,Lokman C,Van Den Hondel C.A and Punt P.J(2003):, The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi. *Microb. Cell Fact.* 2:1.

Kabat E ,Wu T.T,Perry H.M,Gottesman K.S and Foeller C(1991):, Sequence of Proteins of Immunological Interst. US Public Health Services, NIH Bethesda, MD, Publication No. 91

Kabir S and Dwinn T. (2002):, "Immunoglobulin purification by affinity chromatography using protein A mimetic ligands prepared by combinatorial chemical synthesis". *Immunol Invest* 31 (3-4): 263–78

Kabat E, Merguerian M, Han Z, Scholle D.D,Koide S and Kay B.K(2004):, Molecular recognition properties of FN3 monobodies that bidn the Src SH3 domain. *Chem. Biol.* 1:835-844.

Kalyuzhny AE and Ewill N:(2005) :, "Chemistry and biology of the ELISPOT assay". *Methods Mol Biol.* 302: 15–31

Hazaeli M.B, Conry R.M and Lobuglio A.F(1994):, Human response to monoclonal antibodies. *J. Immunother.* 15:42-52

Kipriyanov S.M, Lennin R(2002):, Generation of bispecific and tandem diabodies , *Methods Mol. Biol.* 178: 317-331

Koide A,Bailey C.W, Huang X and Koides S(1998):, The fibronectin type III domain as a scaffold for novel binding proteins. *J. Mol.Biol.* 284:1141-1151

Kohler G and Milstein C(1975):, Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* ; 256: 495-497

Kontermann R.E and Hank G(2004):,: Intrabodies as therapeutic agents. *Methods* 34: 163-170

Korit A.A, Guthrie R.E and Hunds M.G(1995):,Solution properties of Escherichia coli-Solution properties of anti-neuraminidase antibody NC41. *J. Protein Chem.* 14: 167-178.

Krauss WC, Park JW, Kirpotin DB, Hong K and Benz CC.(2000):, Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. *Breast Dis* ; 11: 113-124.

Kruger C, Hultberg A, Marcotte H, Hermans P, Bezemer S, Frenken LG and Hammarstrom L (2006):, Therapeutic effect of llama derived VHH

fragments against *Streptococcus mutans* on the development of dental caries. *Appl Microbiol Biotechnol* 72:732–737

Krueger G, Langley R, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley L and Lebwohl M (2007) : "A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis". *N Engl J Med* 356 (6): 580–92

Kurien B and Scofield R (2006):, "Western blotting". *Methods* 38 (4): 283–93.

Lange IG, Daxenberger A and Meyer HH (2001):, Studies on the antibody response of Lama glama—evaluation of the binding capacity of different IgG subtypes in ELISAs for clenbuterol and BSA. *Vet Immunol Immunopathol* 83:1–9

Laskowski R.A, Luscome N.M, Swindells M.B, Thornton J.M(1996):, Protein clefts in molecular recognition and function. *Protein Sci.*(1996) 5: 2438-2452

Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Holzer W, Genst E, Wyns L and Muyldermans S (1998):, Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. *Embo J* 17:3512–3520

LeBien TW and Meroslave R (2000) . "Fates of human B-cell precursors". *Blood* 96 (1): 9–23

Ledeboer A.M, Bezember S and De Haard J.J(2002):, Preventing phage lysis of *Lactococcus lactis* in cheese production using a neutralizing heavy-chain antibody fragment from llama. *J. Dairy Sci.* 85 :1376-1382.

Lesk AM and Chothia C (1988):, Elbow motion in the immunoglobulins involves a molecular ball-and-socket joint. *Nature* 335:188–190

Lieber MR, Yu K and Raghavan SC (2006):, "Roles of nonhomologous DNA end joining, V(D)J recombination, and class switch recombination in chromosomal translocations". *DNA Repair (Amst.)* 5 (9-10): 1234–45

Litman GW, Rast JP and Shablott MJ (1993):, "Phylogenetic diversification of immunoglobulin genes and the antibody repertoire". *Mol. Biol. Evol.* 10 (1): 60–72

Loris R and Marionovsky Lah J(2003):, Crystal structure of the intrinsically flexible addiction antidote MazE. *J. Biol. Chem.* (2003) 278:28252-28257

Low N.M, Holliger P.H and Winter G(1996):, Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. *J. Mol. Biol.* 260-359-368.

Marrack, JR and Atlan B (1938):, *Chemistry of antigens and antibodies*, 2nd ed., London: His Majesty's Stationery Office. [OCLC 3220539](#).

Mark J.D,Griffiths A.D,Malmaqvist M,Clackson T.P,Bye J.M, and Winter G(1992):, By-passing immunization: Building high affinity human antibodies by chain shuffling. *Biotechnology* (1992) 10: 779-783

Martin F, Volpari C and Steikuhler C(1997):, Affinity selection of a camelised VH domain antibody inhibitor of hepatitis C virus NS3 protease. *Protein Eng.* 10:6-7-614.

Mattu T, Pleass R, Willis A, Kilian M, Wormald M, Lellouch A, Rudd P, Woof J and Dwek R (1998):, "The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions". *J Biol Chem* **273** (4): 2260–72

Mian I, Bradwell A and Olson A (1991):, "Structure, function and properties of antibody binding sites". *J Mol Biol* **217** (1): 133–51

Morrison S.L, Johnson M.J, Herzenberg L.A and OI V.T(1984):, Chimeric human antibody molecules; mouse antigen-binding domains with human constant region domains. *Proc. Natl. Acad. Sci. USA* 21:6851-6855.

Muruganandam A, Tanha J, Narang S and Stanimirovic D (2002):, Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. *Faseb J* 16:240–242

Muyldermans S, Cambillau C (2001):, :Single domain camel antibodies: current status. *J Biotechnol* 74:277–302

Mulydermans S,Cambillau C and Wyns L(2001):, Recognition of antigens by single-domains. *Trends Biochem. Sci.* 26:230-235.

Muyldermans S, Atarhouch T, Sldhana T and Barbosa J.A(1994): „Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. *Protein Eng.* : 1129-1135

Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA and Hamers R (1994): „Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. *Protein Eng* 7:1129–35

Nadler LM, Stashenko P and Hardy R(1980): „ Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma associated antigen. *Cancer Res* ; 40: 3147-3154.

Nemazee D and Kadir A(2006):„ "Receptor editing in lymphocyte development and central tolerance". *Nat Rev Immunol* 6 (10): 728–40.

Neuberger M, Ehrenstein M, Rada C, Sale J, Batista F and Williams G, Milstein C (2000):„ Medical researcher (7):23-25.

Niklolajczyk S.D, Catalona W.J and EvansC.L(2004):„ Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. *Clin. Chem.* 50:1017 – 1025

Nguyen VK, Zou X, Lauwereys M, Brys L, Bruggemann M and Muyldermans S (2003):„ Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells. *Immunology* 109:93–101

Nguyen VK, Hamers R, Wyns L and Muyldermans S (2000):„Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. *Embo J* 19:921–930

Nguyen VK, Hamers R, Wyns L and Muyldermans S (1999): „Loss of splice consensus signal is responsible for the removal of the entire CH1 domain of the functional camel IgG2a heavy-chain antibodies. *Mol. Immunol.* 36:55-524.

Nieba L, Honegger A, Krebber C and Pluckthun A (1997):„Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. *Protein Eng* 10:435–444

Nielsen U.B, Adams G.P., Weiner L.M and Marks J.D(2000):, Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. *Cancer Res.* 60 : 6343-6440.

Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA and Marks JD (2002):, Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. *Proc Natl Acad Sci USA* 99:11346– 11350

O'dell J.R and Bonel V (2004):, Therapeutic strategies for rheumatoid arthritis. *N. Engl. J. Med.* 350: 2591-2602.

Olichon A, Schweizer D, Muyldermans S and De Marco A (2007) ;, Heating as a rapid purification method for recovering correctly-folded thermotolerant VH and VHH domains. *BMC Biotechnol* 7:7

Or-Guil M, Wittenbrink N, Weiser AA and Schuchhardt J (2007):, "Recirculation of germinal center B cells: a multilevel selection strategy for antibody maturation". *Immunol. Rev.* 216: 130–41

Orlani R, Gussow D.H, Jones P.T. and Winter G(1980):, immunoglobulin variable domains for expression by the polymerase chain reaction. *Proc. Natl. Acad. Sci. USA* (1980) 86:3833-3837.

Padlan E.A and Schmitt A(1996):, X-ray crystallography of antibodies. *Adv. Protein Chem.* 49: 57-133.

Padlan E.A and Schmitt A (1994):, Anatomy of the antibody molecule. *Mol. Immunol.* 31: 169-217.

Parker D and Retz C (1993):, "T cell-dependent B cell activation". *Annu Rev Immunol* 11: 331–60.

Panaccione R, Fedorak R.N and Aumais G(2004):, Canadian Association for Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. *Can. J. Gastroenterol.* 18:503-508.

Pankhurst T and Adu D(2004):, antibodies in the prevention of renal allograft rejection, *Expert Opin. Biol. Therap.* 4:243-252.

Pant N, Hultberg A, Zhao Y, Svensson L, Pan-Hammarstrom Q, Johansen K, Pouwels PH, Ruggeri FM, Hermans P, Frenken L, Boren T, Marcotte H and Hammarstrom L (2006):, Lactobacilli expressing variable

domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rota virus induced diarrhea. *J Infect Dis* 194:1580–1588

Pawelek J.M, Brooks K.L and Bermudes D(2003):, Bacteria as tumortargeting vectors. *Lancet Oncol.* 4: 548-556.

Pendeley G, Schantz A and Wanger C(2003):, Immunogenicity of therapeutic monoclonal antibodies. *Curr. Opin. Mol. Ther.* (2003) 5:172-179.

Perez JM, Renisio JG, Prompers JJ, van Platerink CJ, Cambillau C, Darbon H and Frenken LG (2001):, Thermal unfolding of a llama antibody fragment: a two-state reversible process. *Biochemistry* 40:74–83

Peter Parham and sunzy B(2005):, "The Immune System. 2nd ed. Garland Science: New York, pg.47-62

Pier GB, Lyczak JB and Wetzler LM (2004):, *Immunology, Infection, and Immunity*. ASM Press. ISBN 1-55581-246-5

Pleschberger M, Neubauer A and Egelseer E.M (2003):, Generation of a functional mononuclear protein lattice consisting of an S-layer fusion protein comprising the variable domain of a camel heavy-chain antibody. *Bioconjug, Chem.*14:440-448.

Pleschberger M, Saerens D, Weighert S, Sleyer U.B, Muleydermans S and Sara M (2004):, An S-layer heavy chain camel antibody fusion protein for generating of a nanopatterned sensing layer to detect the prostate specific antigen by surface plasmon resonance technique. *Bioconjug. Chem.* 15:664-671.

Plosker G and Figgitt D (2003):, "Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia". *Drugs* **63** (8): 803–43.

Presta LG and Lahr S.J (2006):, Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. *Adv Drug Deliv Rev* 58:640–656

Presta L.G. and Lahr S.J. (2002):, Engineering antibodies for therapy. *Curr. Pharm. Biotechnol.* 3:237-256

Presta LG, Lahr SJ and Shields RL(1993); Humanization of an antibody directed against IgE. *J Immunol.*151: 2623-2632.

Preud'homme JL, Petit I, Barra A, Morel F, Lecron JC and Lelièvre E (2000):, "Structural and functional properties of membrane and secreted IgD". *Mol. Immunol.* **37** (15): 871–87

Putnam FW, Liu YS and Low TL (1979):, "Primary structure of a human IgA1 immunoglobulin. IV. Streptococcal IgA1 protease, digestion, Fab and Fc fragments, and the complete amino acid sequence of the alpha 1 heavy chain". *J Biol Chem* **254** (8): 2865–74.

Rahbarizadeh F, Rasaee MJ, Forouzandeh M and Allameh AA (2006):, Over expression of anti-MUC1 single-domain antibody fragments in the yeast *Pichia pastoris*. *Mol Immunol* **43**:426–435

Rahbarizadeh F, Rasaee MJ, Forouzandeh-Moghadam F. M and Allameh A.A (2005):, High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in *Escherichia coli*. *Protein Expr Purif* **44**:32–38

Rahbarizadeh F, Rasaee MJ, Forouzandeh-Moghadam F. M and Allameh A.A (2004):, Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin . *Hybrid Hybridomics* **23**:15-159.

Raju TN and berg J.(1999):, "The Nobel chronicles. 1972: Gerald M Edelman (b 1929) and Rodney R Porter (1917-85)". *Lancet* **354** (9183): 1040.

Ravetch J and Bolland S (2001):, "IgG Fc receptors". *Annu Rev Immunol* **19**: 275–90

Reen DJ. And Berth H. (1994):, "Enzyme-linked immunosorbent assay (ELISA)". *Methods Mol Biol.* **32**: 461–6.

Reichert JM and Valge-Archer VE (2007):, Development trends for monoclonal antibody cancer therapeutics. *Nat Rev Drug Discov* **6**:349–356

Reiter Y, Scuck P, Boyd L.E and Plaskin D(1999):, An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. *J. Mol. Biol.* **290**-686-698.

Reniso J.G, Romi-Lebrun R and Blance (2002):, Solution structure and backbone dynamics of an antigen-free heavy chain variable domain (VHH) from llama. *Prot. Struct, Funct. Genet.* 47:546-555.

Rhoades RA and Pflanzler RG (2002):, *Human Physiology*, 4th ed., Thomson Learning. ISBN 0-534-42174-1

Reverts H, De Baetselier P and Muyldermans S (2005) :, Nanobodies as novel agents for cancer therapy. *Expert Opin Biol Ther* 5:111–124

Reichmann L and Mulydermans S(1999):, Single-domain antibodies: comparison for camel VH and camelised human VH domains. *J. Immunol. Methods* . 231: 25-38.

Reichmann L and Mulydermans S(1996):, Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain. *J. Mol. Biol.* 259:957-969.

Riechmann L, Clark M and Waldmann H(1988):, Reshaping human antibodies for therapy. *Nature* . 332:323-327.

Ritz J and Schlossman SF(1982):, Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. *Blood*; 59: 1-11

Robert B, Dorvillius M and Buchegger F(1999):, Tumour targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA). *Int. J. Cancer* . 81:285-291.

Roovers R.C, Laeremans T, Huang L, De Taeye S, Verkleij A.J, Reverts H, De Haard H.J and, Van Bergen en Henegouwen P.M (2007):, Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EGFR Nanobodies. *Cancer Immunol Immunother* 56:303–317

Rosebrough S.F. and Dans C (1996):, Two-step immunological approaches for imaging and therapy. *Q. J. Nucl. Med.* . 40:234-251.

Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A, Backmann N, Conrath K, Muyldermans S, Cardoso MC and Leonhardt H (2006):, Targeting and tracing antigens in live cells with fluorescent nanobodies. *Nat Methods* 3:887–889

Roux K and Rus H(1999):, "Immunoglobulin structure and function as revealed by electron microscopy". *Int Arch Allergy Immunol* 120 (2): 85–99.

Rus H, Cudrici C and Niculescu F (2005):, "The role of the complement system in innate immunity". *Immunol Res* **33** (2): 103–12.

Saerens D, Kinne J, Bosmans E, Wernery U, Muyldermans S and Conrath K (2004):, Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. *J Biol Chem* **279**:51965–51972

Sagt CM, Kleizen B, Verwaal R, de Jong MD, Muller WH, Smits A, Visser C, Boonstra J, Verkleij AJ and Verrips CT (2000):, Introduction of an N-glycosylation site increases secretion of heterologous proteins in yeasts. *Appl Environ microbiol* **66**:4940–4944.

Sandbom W.J, and Hanauer S.B(1999):, Antitumor necrosis factor therapy for inflammatory bowel disease; a review of agents, pharmacology, clinical results and safety. *Inflamm. Bowel Dis.***5**: 119-133.

Saez-Llorens X, Castano E and Null D(1998):, Safety and pharmacokinetics of an intramuscular humanized antibody monoclonal antibody to respiratory syncytial virus in premature infants with bronchopulmonary dysplasia. *Pediatr. Infect. Dist.* **17**; 787-791.

Scanziani E. and Jynns(1980):, "Immunohistochemical staining of fixed tissues". *Methods Mol Biol* **104**: 133–40.

Schwaber J and Cohen E(1973) :Human x mouse somatic cell hybrid clones secreting immunoglobulins of both parental types. *Nature* ,**244**.444-447.

Segal D.M, Weiner G. J.(1999):, Bispecific antibodies in cancer therapy. *Curr. Opin. Immunol.* **11**:558-562.

Sethuraman N and Stadheim TA (2006):, Challenges in therapeutic glycoprotein production. *Curr Opin Biotechnol* **17**:341–346

Senter PD and Springer CJ(2001). Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. *Adv Drug Deliv Rev*; **53**:247–64.

Silverstein A.M and Decans L (2004):, "Labeled antigens and antibodies: the evolution of magic markers and magic bullets". *Nat. Immunol.* **5** (12): 1211–7

Silverstein A.M and Decans L (2003):, "Cellular versus humoral immunology: a century-long dispute". *Nat. Immunol.* 4 (5): 425–8

Simmons DP, Abregu FA, Krishnan UV, Proll DF, Streltsov VA, Doughty L, Hattarki MK and Nuttall SD (2006):, Dimerisation strategies for shark IgNAR single domain antibody fragments. *J Immunol Methods* 315:171–184

Smith J.B, Popplewell A and Athwal D(2001):, Prolonged in vivo residence times of antibody fragments associated with albumin. *Bioconjug. Chem.* 12:750-756.

Spinelli S,Tegnomi M,Frenken L, Van Vliet C.and Cambillau C(2001):, Lateral recognition of a dye hapten by a llama VHH domain. *J. Mol. Biol.* 311:123-129.

Spinnelli S ,Frenken L.G and Hermans P (2000):, Camelid heavy-chain variable domains provide efficient combining sites to haptens. *Biochemistry .* 39 :1217-1222.

Spinelli S, Frenken L, Bourgeois D, de Ron L, Bos W, Verrips T, Anguille C, Cambillau C and Tegoni M (1996):, The crystal structure of a llama heavy chain variable domain. *Nat Struct Biol* 3:752– 757

Spinelli S,Tegnomi M,Frenken L, Van Vliet C.and Cambillau C(2001):, Lateral recognition of a dye hapten by a llama VHH domain. *J. Mol. Biol.* 311:123-129.

Stanfield R.L,Dooley H,Flajnik M.F. and Wilson I.A (2004):, Crystal structure of a shark single-domain antibody V region in complex with lysozyme, *Science* 305: 1770-1773

Stavnezer J and Amemiya CT (2004):, "Evolution of isotype switching". *Semin. Immunol.* 16 (4): 257–75

Stern P and Zhen B (2006):, "Current possibilities of turbidimetry and nephelometry". *Klin Biochem Metab* 14 (3): 146–151.

Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, Wyns L, Senter P, Revets H, De Baetselier P, Muyldermans S and Magez S (2004):, Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. *J Biol Chem* 279:1256–1261

Streltsov VA, Varghese JN, Carmichael JA, Irving RA, Hudson PJ and Nuttall SD (2004):, Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell surface receptor. *Proc Natl Acad Sci USA* 101:12444–12449

Stern M and Herrmann R(2005):,. Overview of monoclonal antibodies in cancer therapy: present and promise. *Crit Rev Oncol Hematol* 54: 11-29.

Stevens FJ, Solomon A and Schiffer M (1991). "Bence Jones proteins: a powerful tool for the fundamental study of protein chemistry and pathophysiology". *Biochemistry* 30 (28): 6803–5

Sundaresan G, Yazaki P.G and Shivekly J.E (2003):,labeled engineered anti-CEA minibodies and diabodies allow high contrast, antigen-specific small-animal PET imaging of xenografts in mice. *J. Nucl. Med.*44:1962-1969.

Sundberg EJ and Mariuzza RA (2002):, Molecular recognition in antibody antigen complexes. *Adv Protein Chem* 61:119–160

Tanha J, Dubuc G, Hirama T, Narang S.A and MacKenzie C.R ,(2002) Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties. *J Immunol Methods* 263:97–109

Tanha J, Xup and Chen Z (2001):,design features of camelised human single domain antibody libraries. *J. Biol. Chem.* 276 : 24774-24780.

Tini M, Jewell UR, Camenisch G, Chilov D and Gassmann M (2002):,. "Generation and application of chicken egg-yolk antibodies". *Comp. Biochem. Physiol., Part a Mol. Integr. Physiol.* 131 (3): 569–74

Thomassen YE, Verkleij AJ, Boonstra J and Verrips CT (2005):, Specific production rate of VHH antibody fragments by *Saccharomyces cerevisiae* is correlated with growth rate, independent of nutrient limitation. *J Biotechnol* 118:270–277

Thomassen YE, Meijer W, Sierkstra L and Verrips CT (2002):, Large-scale production of VHH antibody fragments by *Saccharomyces cerevisiae*. *Enzyme Microb Technol* 30:273–278

Todorovska A, Roovers R.C and Dolezal O (2001):,Design and application of diabodies, triabodies for cancer targeting. *J. Immunol. Methods* . 248:47-66. 1.

Tolar P, Sohn HW and Pierce SK (2008):, "Viewing the antigen-induced initiation of B-cell activation in living cells". *Immunol. Rev.* 221: 64–76. doi:10.1111/j.1600-065X.2008.00583.x. PMID 18275475.

Tomasi TB, veen B(1992). "The discovery of secretory IgA and the mucosal immune system". *Immunol. Today* 13 (10): 416–8.

Transue T.R,De Genst E,Gharhoudi M.A,Wyns L and Mulydermans S(1998):,Camel signledomain antibody inhibits enzyme by mimicking carbhydrate substrate. *Prot. Struct. Funct. Genet.* 32:515-522.

Underdown B and Schiff J (1986):, "Immunoglobulin A: strategic defense initiative at the mucosal surface". *Annu Rev Immunol* 4: 389–417.

Urbaniak S and Greiss M (2000):,. "RhD haemolytic disease of the fetus and the newborn". *Blood Rev* 14 (1): 44–61.

Utsumi S and Karush F (1964):, The subunits of purified rabbit antibody. *Biochemistry* 3:1329–1338

Van Epps HL Dennis C (2006):, "Michael Heidelberger and the demystification of antibodies". *J. Exp. Med.* 203 (1): 5

Van de Laar T, Visser C, Holster M, Lopez CG, Kreuning D, Sierkstra L, Lindner N and Verrips T (2007) :Increased heterologous protein production by *Saccharomyces cerevisiae* growing on ethanol as sole carbon source. *Biotechnol Bioeng* 96:483–494

Van der Linden R.H, Frenken L.G, De Geus B, Harmsen M.M, Ruuls R.C, Stok W, de Ron L, Wilson S, Davis P and Verrips C.T (1999):, Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. *Biochim Biophys Acta* 1431:37–46

Van der Linden R.H, De Geus B, Stok W, Bos W, Van Wassenaar D,Verrips T and Frenken L (2000a):, Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. *J Immunol Methods* 240:185–195

Van der Linden R.H, De Geus B, Frenken G.J, Peters H and Verrips C.T (2000b):, Improved production and function of llama heavy chain antibody fragments by molecular evolution. *J Biotechnol* 80:261–270

Van der Vaart J.M, Pant N, Wolvers D, Bezemer S, Hermans P.W, Bellamy K, Sarker S.A, van der Logt C.P, Svensson L, Verrips C.T, Hammarstrom L and van Klinken B.J (2006):, Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. *Vaccine* 24:4130–4137 .

Van Der Vaart J.M and Pant N(2002):, Expression of VHH antibody fragments in *Saccharomyces cerevisiae*. *Methods Mol. Biol.* .178: 359-366.

Van Koningsbruggen S, De Harrd H and De Kiveit P(2003):, Llama derived phage display antibodies in the dissection of the human disease oculopharyngeal muscular dystrophy. *J. Immunol. Methods* 279: 149-161.

Veiga E ,De Lorenzo V and Fernandez L.A.(2004):, Structural tolerance of bacterial autotransporter for folded passenger protein domains. *Mol. Microbiol.* 52;1069-1080

Verheesen P, ten Haaft MR, Lindner N, Verrips CT, de Haard JJ (2003) Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immunoperfusion chromatography. *Biochim Biophys Acta* 1624:21–28

Verheesen P, Roussis A, de Haard HJ, Groot AJ, Stam JC, den Dunnen JT, Frants RR, Verkleij AJ, Verrips CT and van der Maarel SM (2006) Reliable and controllable antibody fragment selections from camelid.

Visintin M, Quondam M and Cattaeno A(2002):, The intracellular antibody capture technology (IACT) : towards a consensus sequence for intracellular antibodies. *J. Mol. Biol.* 317:73-83.

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L, Slamon D, Murphy M, Novotny W, Burchmore M, Shak S and Stewart S (2001). "First-line Herceptin monotherapy in metastatic breast cancer". *Oncology* 61 Suppl 2: 37–42.

Voordijk S, Hansson T, Hilvert D and Van Gunstern W.F(2000):, Molecular dynamics simulations highlight mobile regions in proteins: a novel

suggestion for converting a murine VH domain into a more tractable species. *J. Mol. Biol.* 963-973.

Vranken W ,Tolkachev D and Xu P(2002):, Solution structure of a llama single-domain antibody with hydrophobic residues typical of the VH/VL interface. *Biochemistry* 41: 8570-8679.

Vu KB, Ghahroudi MA, Wyns L and Muyldermans S (1997):, Comparison of llama VH sequences from conventional and heavy chain antibodies. *Mol Immunol* 34:1121–1131

Waibel R, Albel R, Alberto R and Willuda J(1999):, Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(1)-carbonyl complex. *Nat . Biotechnol.* 17:897-901

Ward E.S, Gussow D.H, Griffith D.S ,Jones P.T and Winter G(1989):, Binding activities of a single immunoglobulin variable domain secreted from *E. coli*. *Nature* 341:544-546

Webster D.M, Henry A.H and Rees A.R(1994):, Antibody-antigen interactions. *Curr. Opin. Struct. Biol.* 4:123-129.

Weir A.N., Nesbitt A, Chapman A.P, Popplewell A.G, Antoniw and Lawson A.D(2002):, Formatting antibody fragments to mediate specific therapeutic functions. *Biochem. Soc. Trans.* 30: 512-516

Whitlow M, Bell B.A, Feng S.L, Filpula D, Hardman K.D, Hubert S.L, Rollence M.L, Wood J.F, Schott ME and Milenic D. (1993):, An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. *Protein Eng* 6:989– 995

Williams N and Fasset N (2000):,. "Immunoprecipitation procedures". *Methods Cell Biol* 62: 449–53

Willuda J, Hongger A and Waibel R(1991):, High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. *Cancer Res.* 59:5758-5767^d

Winau F, Westphal O and Winau R (2004):, "Paul Ehrlich--in search of the magic bullet". *Microbes Infect.* 6 (8): 786–9.

Winter G, Griffith A.D, Kawkins R.E and Hoogen-Boom H.R (1994):, Making antibodies by phage display technology. *Annu. Rev. Immunol.* 12:433-455.

Winter G and Milestein C(1991):, Man-made antibodies. *Nature* 349:293-299

Wintrobe, Maxwell Myer (2004):, *Wintrobe's clinical hematology*, John G. Greer, John Foerster, John N Lukens, George M Rodgers, Frixos Paraskevas, 11, Hagerstown, MD: Lippincott Williams & Wilkins, 453-456. ISBN 0-7817-3650-1

Woof J and Burton D (2004):, "Human antibody-Fc receptor interactions illuminated by crystal structures". *Nat Rev Immunol* 4 (2): 89–99

Woolven B.P, Frenken L.G, Van Der Logt P and Nichollis P.J (1999):, The structure of the llama heavy-chain constant genes reveals a mechanism for heavy-chain antibody formation. *Immunogenetics* 50:98-101.

Worn A and Pluckthun A (2001):, Stability engineering of antibody single-chain Fv fragments. *J. Mol. Biol.* 305: 989-1010.

Wu A.M., Yazki P.J(2000):, Designer genes; recombinant antibody fragments for biological imaging. *W.J. Nucl. Med.* 44: 268-283

Wu T.T ,Johnson G and Kabat E.A (1993):, Length distribution of CDRH3 in antibodies. *Proteins* 16:1-7.

Yau K.Y, Groves M.A, Li S, Sheedy C, Lee H, Tanha J, MacKenzie CR, Jermutus L and Hall JC (2003) :, Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library. *J Immunol Methods* 281:161–175

Yokota T, Milenic D.E, Whitlow M and Schlom J(1990):, Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. *Cancer Res.* 9: 139-134.

Yoo TJ, Roholt OA and Pressman D (1967):, Specific binding activity of isolated light chains of antibodies. *Science* 157:707–709

Zhang J, Tanha J, Hiramata T, Khieu N.H, To R, Tong-Sevinc H, Stone E, Brisson JR and MacKenzie C.R (2004) :, Pentamerization of single domain

antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. *J Mol Biol* 335:49–56

Zuckier L.S and Denardo G.L(1997):, Trials and tribulations: oncological antibody imaging comes to the fore. *Semin. Nucl. Med.* 27:10-29.

Zwick M.B, Parren P.W, Saphire E.O, Church S, Wang M, Scott J.K, Dawson PE, Wilson IA and Burton D.R(2003):, Molecular features of the broadly neutralizing immunoglobulin 15:12-27.